文献速递前列腺癌

中国前列腺癌患者胚系DNA修复基因突变图谱

Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
PubMed 文献 · Eur Urol · 2019-06-24

研究对316例中国前列腺癌患者进行18个DNA修复基因胚系测序,9.8%(31/316,95%CI 6.5-13%)携带致病突变,其中BRCA2占6.3%、BRCA1占0.63%、ATM占0.63%、其他15个基因占2.5%。尽管中美前列腺癌风险差异大,胚系DNA修复基因突变频率相似。研究确认中国前列腺癌患者需进行基因检测,并鉴于种族多样性,呼吁全面分析详细突变谱以进一步优化管理策略。

要点

  • 316例中国前列腺癌患者中9.8%携带18个DNA修复基因胚系致病突变。
  • BRCA2突变占6.3%,BRCA1和ATM各占0.63%,其他15个基因合计占2.5%。
  • 中国与西方前列腺癌风险差异大,但胚系DNA修复基因突变频率相似。

核心结论

  • 中国前列腺癌患者胚系DNA修复基因突变频率与西方人群相似,尽管中美前列腺癌风险差异大。
  • 研究确认中国前列腺癌患者进行基因检测的必要性。
  • 鉴于种族多样性,作者呼吁全面分析详细突变谱以进一步优化管理策略。

研究设计与样本

  • 对316例中国前列腺癌患者进行18个DNA修复基因的胚系测序。

主要发现

  • 9.8%(31/316,95%CI 6.5-13%)携带18个前列腺癌相关DNA修复基因致病突变。
  • BRCA2突变占6.3%,BRCA1占0.63%,ATM占0.63%,其他15个基因合计占2.5%。
  • 中国与西方前列腺癌风险差异大,但胚系DNA修复基因突变频率相似。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic testing for prostate cancer (PCa) patients is in constant development. Specific genetic alterations indicate personalized managing strategies, requiring clinicians to refer appropriate patients for genetic testing. However, our understanding of genetic epidemiology of PCa is mainly based on data from Caucasian populations. In addition, there is evidence that alterations in DNA repair genes (DRGs) may be ethnic specific in other cancers such as breast cancer. Thus, whether Caucasian-based genetic information can be used to guide clinical practice in Chinese population remains unknown. Aiming to clarify the landscape of germline DRG mutation in Chinese patients with PCa, we sequenced 316 patients for 18 DRGs. Among all cases, 9.8% (31/316, 95% confidence interval [CI]: 6.5-13%) carried pathogenic mutations in 18 PCa-related DRGs: 6.3% in BRCA2, 0.63% in BRCA1, 0.63% in ATM, and 2.5% in 15 other genes. Overall, we observed similar germline DRG mutation frequencies, although there is large disparity in the risk of PCa between China and the West. Our study called for a comprehensive analysis in detailed mutation spectra to refine management strategies further, given the ethnic diversity. PATIENT SUMMARY: We sequenced germline pathogenic mutations in 18 DNA repair genes in 316 patients and elucidated the mutation landscape of Chinese prostate cancer (PCa) patients. Our study confirmed the necessity of genetic testing in Chinese PCa and called for a comprehensive analysis in detailed mutation spectra to refine management strategies further, given the ethnic diversity.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wei Y, Wu J, Gu W, et al. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. Eur Urol. 2019. PMID: 31248605. doi:10.1016/j.eururo.2019.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。